한빛사 논문
Kah Yee Goh1 Kah Weng Lau2,3 Terence You De Cheng3 Su Chin Tham3 Chwee Teck Lim4,5 Narayanan Gopalakrishna Iyer6,7 Su Bin Lim8 Darren Wan-Teck Lim1,3,7
1Division of Medical Oncology, National Cancer Centre Singapore, Singapore 169610 2Department of Pathology, National University Hospital, Singapore 119074 3A*STAR, Proteos, Institute of Molecular and Cell Biology, Singapore 138673 4Department of Biomedical Engineering, Mechanobiology Institute, National University of Singapore, T-Lab, Singapore 117411 5Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, MD6, Singapore 117599 6Department of Head and Neck Surgery, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore 169610 7Office of Academic and Clinical Development, Duke-NUS Medical School, Singapore 169857 8Department of Biochemistry and Molecular Biology, Ajou University School of Medicine, Yeongtong-Gu, Suwon 16499, South Korea
Correspondence Darren Wan-Teck Lim, Su Bin Lim
Abstract
Dear Editor,
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally [1, 2]. Despite the improvement in treatment modalities, up to 50% of HNSCC patients still develop recurrent/metastatic (R/M) disease [3], and platinum-based chemotherapy with cetuximab and/or pembrolizumab has become the standard of care [4]. However, R/M HNSCC is challenging to treat, the prognosis is poor, and there is an unmet need for new therapeutic targets.
논문정보
관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기